Gene · 7357
Papers2,116
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,116
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Repurposing Gaucher disease therapy for Saposin C deficiency: Proof-of-concept with eliglustat. | Mol Genet Metab | 2026 | 41812503 | PubTator, text mining | PubMed |
| ORMDL Proteins Turnover via Proteasome and Autophagy Is Cell-Type Dependent and Tied to Ceramide Homeostasis. | FASEB J | 2026 | 41806112 | PubTator, text mining | PubMed |
| Eliglustat prevents acute kidney injury caused by Shiga toxin 2 in lethal and sublethal rat models of hemolytic uremic syndrome. | Front Pharmacol | 2026 | 41800087 | PubTator, text mining | PubMed |
| Plasma Sphingolipid Profiling Predicts Radiosensitivity in Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2026 | 41777869 | PubTator, text mining | PubMed |
| Integrated analysis and validation of metabolism-related genes in lung transplantation-induced cold ischemia/ reperfusion injury. | PeerJ | 2026 | 41769389 | PubTator, text mining | PubMed |
| Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease. | Ther Adv Rare Dis | 2026 | 41769220 | PubTator, text mining | PubMed |
| Rare-variant burden across lysosomal genes implicates sialylation and ganglioside metabolism in Parkinson's disease. | medRxiv | 2026 | 41757160 | PubTator, text mining | PubMed |
| Decoding the Role of Lipid Metabolism and Membrane Dynamics in Melanoma. | Int J Mol Sci | 2026 | 41751850 | PubTator, text mining | PubMed |
| Glucosylsphingosine (Lyso-Gb1): An Update on Its Use as a Biomarker in Gaucher Disease. | Int J Mol Sci | 2026 | 41751844 | PubTator, text mining | PubMed |
| Targeting Glycolytic Metabolism in Cancer Therapy: Current Approaches and Future Perspectives. | Cells | 2026 | 41744805 | PubTator, text mining | PubMed |
| Targeting UGCG sensitizes AML cells to venetoclax through RAB32-mediated endoplasmic reticulum-mitochondria communication. | Cell Rep | 2026 | 41734065 | PubTator, text mining | PubMed |
| Metabolic plasticity of sphingolipids governs cancer cell fitness in acidic tumor ecosystems. | bioRxiv | 2026 | 41726913 | PubTator, text mining | PubMed |
| Direct-to-Biology: Streamlining the Path From Chemistry to Biology in Drug Discovery. | ChemMedChem | 2026 | 41716046 | PubTator, text mining | PubMed |
| Asymmetric Total Syntheses of Eliglustat and C2-epi-Eliglustat. | J Org Chem | 2026 | 41693690 | PubTator, text mining | PubMed |
| Adverse Event Profile Differences Between Eliglustat and Miglustat: A Pharmacovigilance Study using the U.S. Food and Drug Administration Adverse Event Reporting System. | Drug Res (Stuttg) | 2026 | 41643715 | PubTator, text mining | PubMed |
| RNA-Based Therapies for Inherited Metabolic Disorders. | J Inherit Metab Dis | 2026 | 41621836 | PubTator, text mining | PubMed |
| Multi-omics insights into GBA1-associated Parkinson's disease: interplay of genomics, transcriptomics, proteomics, and lipidomics. | Mol Neurodegener | 2026 | 41612462 | PubTator, text mining | PubMed |
| Drug-induced urinary incontinence in pediatric patients: A disproportionality analysis of the FDA Adverse Event Reporting System. | Medicine (Baltimore) | 2026 | 41560109 | PubTator, text mining | PubMed |
| Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension. | Nat Commun | 2026 | 41519901 | PubTator, text mining | PubMed |
Concurrent inhibition of FLT3 and sphingosine kinase-1 triggers synergistic cytotoxicity in midostaurin resistant FLT3-ITD positive acute myeloid leukemia cells via blocking FLT3/STAT5A signaling to induce apoptosis. | J Chemother | 2026 | 40119531 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7357/papers?page=2